New insider activity at Medpace Holdings ( (MEDP) ) has taken place on December 3, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CEO August J. Troendle has recently sold 28,876 shares of Medpace Holdings stock, amounting to a total transaction value of $17,114,846.
Recent Updates on MEDP stock
BMO Capital has initiated coverage of Medpace Holdings with a Market Perform rating, citing the stock’s current valuation as full amidst a “tepid” biotech funding environment. The firm notes that the current share price leaves little room for potential macroeconomic volatility, suggesting cautious optimism in the near term.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 74.37%
Average Trading Volume: 311,548
Technical Sentiment Signal: Buy
Current Market Cap: $16.44B